<DOC>
	<DOCNO>NCT00023439</DOCNO>
	<brief_summary>This pilot study evaluate performance several nucleic acid amplification methodology diagnosis management active tuberculosis</brief_summary>
	<brief_title>TBTC NAA Study : Pilot Study Surrogate Markers Outcome TB Treatment</brief_title>
	<detailed_description>This study evaluate potential surrogate marker treatment failure relapse substudy ongoing Tuberculosis Trials Consortium ( TBTC ) disease treatment study . After enrollment complete , specimens case treatment failure relapse evaluate comparison control sample measure prognostic value follow test : 1 ) quantitative rRNA 2-month sputum predict relapse , 2 ) MTB 85B mRNA detect reactivation , 3 ) 1- 4-month NAA broth culture test predict relapse , 4 ) mRNA , rRNA DNA end therapy predict relapse , 5 ) sputum rRNA blood DNA detect recurrence prodrome , 6 ) sputum rRNA compare culture diagnose `` paradoxical reaction , '' 7 ) compare blood DNA culture end induction end treatment , 8 ) compare accuracy different NAA assay standard culture , 9 ) determine MTD rRNA assay positive negative conversion time , 10 ) characterize quality quantity sputum time relation culture clinical outcome , 11 ) ass ability clinical , radiographic , microbiologic risk factor predict treatment failure relapse .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . ( 1 ) Enrollment another TBTC treatment study , ( 2 ) Suspected cultureconfirmed pulmonary TB ( designate `` NAA2 '' ) . Acceptable indicator suspect tuberculosis culture positive AFB smear positive M. tuberculosis NAA test MTB . 2 . ( For NAA2 case ) : Collection sputum specimen NAA processing , obtain interval 14 day , 17 day start antituberculosis treatment . 3 . Physician recommendation patient willingness receive tuberculosis therapy describe another TBTC treatment trial accordance CDC/ATS recommendation outline : Induction phase therapy initiate 4drugs ( isoniazid , PZA , rifamycin either ethambutol streptomycin ) directly observe therapy ( DOT ) . The induction regimen : 1 . Induction regimens must least 40 DOT dos ( daily ) least 56 DOT daily dose equivalent ( twice weekly ) . No 2 every 7 total dos may selfadministered . Total induction dos ( DOT selfadministered ) exceed 70 . Induction complete within 12 week 2 . The ethambutol streptomycin may discontinue patient continue adequate induction therapy INH , rifampin PZA , M. tuberculosis isolate susceptible INH rifampin . If induction regimen tolerate patient , rifampincontaining regimen compatible CDC/ATS recommendation acceptable alternative . 4 . Age 18 year old 5 . Willingness practice effective contraception ( female childbearing potential ) 6 . Provision write informed consent . Signed patient investigator , accordance Institutional Review Board requirement Treatment drug ( ) high antimycobacterial activity 15 day two month PRIOR start antituberculosis treatment , unless coenrolled TBTC Study 23 , TBTC Study 24 another TBTC treatment study . Patients extrapulmonary tuberculosis , unless coenrolled TBTC Studies 23 , TBTC Study 24 , another TBTC treatment study . Skeletal tuberculosis Silicotuberculosis Patient intolerance rifamycins , MTB resistance rifamycins Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>